<DOC>
	<DOCNO>NCT02497287</DOCNO>
	<brief_summary>The purpose open-label , multicenter study assess long term safety efficacy intranasal esketamine plus oral antidepressant participant treatment-resistant depression ( TRD ) .</brief_summary>
	<brief_title>A Long-term , Safety Efficacy Study Intranasal Esketamine Treatment-resistant Depression</brief_title>
	<detailed_description>This open-label ( researcher participant know treatment participant receiving ) , multicenter ( 1 study site ) , long-term safety efficacy study intranasal esketamine plus oral antidepressant participant treatment-resistant depression ( TRD ) . Participants enter study either directly ( direct-entry participant ) complete Double-Blind Induction Phase ESKETINTRD3005 ( transferred-entry participant ) . The study consist 4 phase : Screening Phase ( 4 week ) , Open-Label Induction Phase ( 4 week ) , Open-Label Optimization/Maintenance phase ( 48 week ) , Follow Phase ( 4 week ) . Transferred entry non-responders ESKETINTRD3005 may enter study Open-Label Induction Phase responder ESKETINTRD3005 may enter Optimization/Maintenance phase . In Open-Label Induction Phase , participants self-administer flexibly-dosed intranasal esketamine ( participant less ( &lt; ) 65 year old self-administer 56 mg 84 mg dose , participant great equal ( &gt; = ) 65 year old self-administer 28 mg , 56 mg 84 mg dose ) twice weekly 4 week . The start dose participant &gt; = 65 year old 28 mg . In addition , direct-entry participant assign receive 1 4 select oral antidepressant medication ( escitalopram sertraline duloxetine venlafaxine extend release [ XR ] ) , initiate Day 1 open-label induction phase continue duration study . Transferred-entry participant continue antidepressant ESKETINTRD3005 duration study . Participants responder end Open-Label Induction phase transferred-entry responder participant ( study ESKETINTRD3005 ) enter Optimization/Maintenance Phase intranasal esketamine treatment session reduce induction phase ( twice weekly ) weekly first 4 week phase , individualize either weekly every week base severity depressive symptom . Participants ' safety depressive symptom assess monitor throughout study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>A ) . For DirectEntry Participants At time sign informed consent form ( ICF ) , participant must man woman â‰¥18 ( old minimum legal age consent country study take place great [ &gt; ] 18 ) At start screen phase , participant must meet Diagnostic Statistical Manual Mental Disorders ( DSM5 ) diagnostic criterion singleepisode major depressive disorder ( MDD ) ( singleepisode MDD , duration must great equal [ &gt; = ] 2 year ) recurrent MDD , without psychotic feature , base upon clinical assessment confirm MiniInternational Neuropsychiatric Interview ( MINI ) At screening , participant must MADRS total score &gt; =22 At start screen phase , participant must nonresponse &gt; =2 oral antidepressant treatment current episode depression , assess use MGHATRQ confirm document record ( example medical/pharmacy/prescription record letter treat physician , etc , ) B ) . For Transferredentry Participants All participant complete doubleblind induction phase ESKETINTRD3005 study , regardless response status , eligible participate study , meet study specific eligibility criteria A ) . For DirectEntry Participants Participant 's depressive symptom previously respond : Esketamine ketamine current major depressive episode per clinical judgment All 4 oral antidepressant treatment option available respective country openlabel induction phase ( , duloxetine , escitalopram , sertraline , venlafaxine XR ) current major depressive episode ( base Massachusetts General Hospital Antidepressant Treatment Response Questionnaire [ MGHATRQ ] ) Participant current prior DSM5 diagnosis psychotic disorder MDD psychotic feature , bipolar relate disorder ( confirm MINI ) , obsessive compulsive disorder ( current ) , intellectual disability ( DSM5 diagnostic code 317 , 318.0 , 318.1 , 318.2 , 315.8 , 319 ) , autism spectrum disorder , borderline personality disorder , antisocial personality disorder , histrionic personality disorder , narcissistic personality disorder Participant homicidal ideation/intent , per investigator 's clinical judgment , suicidal ideation intent act within 6 month prior start screen phase , per investigator 's clinical judgment base Columbia Suicide Severity Rating Scale ( CSSRS ) Participants history moderate severe substance alcohol use disorder accord DSM5 criterion Participants Mini Mental State Examination ( MMSE ) &lt; 25 ; Has neurodegenerative disorder ( example , Alzheimer 's disease , vascular dementia , Parkinson 's disease ) , evidence mild cognitive impairment ( MCI ) B ) . TransferredEntry Participants Participant take prohibited therapy would permit dose Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment-resistant Depression</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Oral Antidepressant</keyword>
</DOC>